Premium
The PHLDB 1 rs498872 (11q23.3) polymorphism and glioma risk: A meta‐analysis
Author(s) -
Gao Xingchun,
Mi Yajing,
Yan Aili,
Sha Baoyong,
Guo Na,
Hu Zhifang,
Zhang Ni,
Jiang Fengliang,
Gou Xingchun
Publication year - 2015
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.12211
Subject(s) - meta analysis , glioma , single nucleotide polymorphism , genetic model , snp , medicine , subgroup analysis , oncology , publication bias , population stratification , genotype , bioinformatics , biology , genetics , gene
The association between the rs498872 single nucleotide polymorphism ( SNP ) and glioma risk has been studied, but these studies have yielded conflicting results. In order to explore this association, we performed a meta‐analysis. A comprehensive literature search was performed using P ub M ed and EMBASE database, with the last search up to A ugust 23, 2013. Six articles including 10 case‐control studies in E nglish with 18 002 controls and 8434 cases were eligible for the meta‐analysis. Subgroup analyses were conducted by source of controls and ethnicity. The combined results showed that rs498872 polymorphism was significantly associated with glioma risks ( TT vs CC : OR = 1.337, 95% CI = 1.222–1.462; TC vs CC : OR = 1.173, 95% CI = 1.081–1.272; dominant model: OR = 1.199, 95% CI = 1.101–1.306; recessive model: OR = 1.237, 95% CI = 1.135–1.347; additive model: OR = 1.156, 95% CI = 1.085–1.232). Moreover, there was increased cancer risk in all genetic models after stratification of the SNP data by the source of controls and ethnicity, and no evidence of publication bias was produced. Our meta‐analysis suggested that rs498872 polymorphism was associated with increased risk of glioma. However, additional studies exploring the combined effects of rs498872 polymorphisms in A sian population should be investigated.